Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals has $66 highest and $27 lowest target. $47.64’s average target is 22.47% above currents $38.9 stock price. Supernus Pharmaceuticals had 36 analyst reports since August 26, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $28 target in Thursday, August 4 report. The firm earned “Hold” rating on Thursday, August 3 by Piper Jaffray. The rating was maintained by Stifel Nicolaus on Tuesday, January 2 with “Buy”. The firm earned “Buy” rating on Monday, July 17 by Stifel Nicolaus. On Wednesday, October 28 the stock rating was initiated by Northland Capital with “Outperform”. FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Monday, November 20 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Monday, November 6. On Monday, October 23 the stock rating was maintained by Cowen & Co with “Buy”. The firm earned “Buy” rating on Wednesday, September 27 by Cantor Fitzgerald. The firm has “Buy” rating by Jefferies given on Friday, October 6.
Investment Technology Group, Inc. operates as an independent broker and financial technology firm in the United States, Canada, Europe, and the Asia Pacific. The company has market cap of $646.15 million. The firm offers various solutions for asset managers and broker-dealers in the areas of execution services, workflow technology, and analytics that provide trade execution services and solutions for portfolio management, as well as investment research, pre-trade analytics, and post-trade analytics and processing. It currently has negative earnings. The firm offers ITG Algorithms and ITG Smart Router that offers portfolio managers and traders to trade orders; POSIT for continuous and scheduled crossing of non-displayed equity orders and price improvement opportunities; ITG Derivatives for electronic listed futures and options trading; ITG Commission Manager, a Web commission management portal; and securities lending services.
Investors sentiment decreased to 0.98 in 2017 Q3. Its down 0.34, from 1.32 in 2017Q2. It worsened, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. The North Carolina-based Retail Bank Of America Corp De has invested 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). New York-based Hutchin Hill Limited Partnership has invested 0.05% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Pictet Asset Mgmt Ltd, a United Kingdom-based fund reported 491,283 shares. State Of Alaska Department Of Revenue reported 9,969 shares or 0.02% of all its holdings. Manufacturers Life Com The stated it has 36,115 shares or 0% of all its holdings. 15,259 were accumulated by Da Davidson Co. First Republic Inv Management Incorporated holds 10,933 shares or 0% of its portfolio. 73,903 are owned by Citadel Advsr Ltd Com. Acadian Asset Mgmt Llc has 1.26M shares. Bruce And Company invested in 1.59% or 178,058 shares. Bamco Ny reported 0.02% stake. Vanguard Grp Inc has 4.49 million shares for 0.01% of their portfolio. Quantbot Techs Lp reported 0.02% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Northern stated it has 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). 73,869 are owned by Nicholas Invest Prtn Ltd Partnership.
Since September 7, 2017, it had 0 buys, and 10 sales for $15.31 million activity. Bhatt Padmanabh P. had sold 20,000 shares worth $960,716. 50,000 shares were sold by PATRICK GREGORY S, worth $2.18 million. Vaughn Victor had sold 5,750 shares worth $258,928. Shares for $4.43 million were sold by Schwabe Stefan K.F..
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.99 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 36.02 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.
The stock increased 2.10% or $0.8 during the last trading session, reaching $38.9. About 1.01 million shares traded or 67.68% up from the average. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since March 1, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.
The stock decreased 0.80% or $0.16 during the last trading session, reaching $19.82. About 401,795 shares traded or 51.86% up from the average. Investment Technology Group, Inc. (ITG) has risen 12.80% since March 1, 2017 and is uptrending. It has underperformed by 3.90% the S&P500.
Analysts await Investment Technology Group, Inc. (NYSE:ITG) to report earnings on May, 2. They expect $0.08 earnings per share, down 50.00% or $0.08 from last year’s $0.16 per share. ITG’s profit will be $2.61 million for 61.94 P/E if the $0.08 EPS becomes a reality. After $0.12 actual earnings per share reported by Investment Technology Group, Inc. for the previous quarter, Wall Street now forecasts -33.33% negative EPS growth.
The post Cantor Fitzgerald Keeps a “Buy” Rating on Supernus Pharmaceuticals (SUPN) and $52.0 Target; Investment Technology Group Has 2.5 Sentiment appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/01/cantor-fitzgerald-keeps-a-buy-rating-on-supernus-pharmaceuticals-supn-and-52-0-target-investment-technology-group-has-2-5-sentiment/
No comments:
Post a Comment